Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research1,190

Loading search results…

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research1,190

FiltersClear all

Status

Recruiting350
Not yet recruiting11
Enrolling by invitation17
Active, not recruiting322
Completed358
Terminated132

Study type

Interventional1,190
Observational101
Expanded access19
Not on ClinicalTrials.gov1,519

Phase

Phase 3325
Not applicable304
Phase 2286
Phase 1103
Phase 1/277
Phase 454

Investigator

Gail J Roboz41
Manish A Shah27
Parag Goyal23
Sonal Kumar23
Scott T. Tagawa22

Show all 50Show fewer

Department

Medicine750
Pediatrics81
Neurology46
Psychiatry46
Obstetrics and Gynecology41

Show all 22Show fewer

Condition

Leukemia, Myeloid, Acute50
Prostatic Neoplasms49
Breast Neoplasms41
Heart Failure31
Neoplasms31

Show all 50

Intervention type

Drug788
Other176
Device166
Biological150
Procedure119
Behavioral83

Sponsor type

Industry685
WCM (investigator-initiated)230
Other academic173
NIH76
Cooperative group25
Unknown1

Start date

Has results posted342

Interventional×Clear all

Showing 21–40 of 1,190 studiesSort:

Active, not recruitingInterventional · Phase 1NCT03190278 ↗
Phase I, Open Label Dose Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence, and Clinical Activity of UCART123 (Allogeneic Engineered T-cells Expressing Anti-CD123 Chimeric Antigen Receptor), Administered in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Gail J RobozPI
Intervention
Biological: UCART123v1.2

FiltersClear all

Status

Recruiting350
Not yet recruiting11
Enrolling by invitation17
Active, not recruiting322
Completed358
Terminated132

Study type

Interventional1,190
Observational101
Expanded access19
Not on ClinicalTrials.gov1,519

Phase

Phase 3325
Not applicable304
Phase 2286
Phase 1103
Phase 1/277
Phase 454

Investigator

Gail J Roboz41
Manish A Shah27
Parag Goyal23
Sonal Kumar23
Scott T. Tagawa22

Show all 50Show fewer

Department

Medicine750
Pediatrics81
Neurology46
Psychiatry46
Obstetrics and Gynecology41

Show all 22Show fewer

Condition

Leukemia, Myeloid, Acute50
Prostatic Neoplasms49
Breast Neoplasms41
Heart Failure31
Neoplasms31

Show all 50

Intervention type

Drug788
Other176
Device166
Biological150
Procedure119
Behavioral83

Sponsor type

Industry685
WCM (investigator-initiated)230
Other academic173
NIH76
Cooperative group25
Unknown1

Start date

Has results posted342

Interventional×Clear all

Showing 21–40 of 1,190 studiesSort:

Active, not recruitingInterventional · Phase 1NCT03190278 ↗
Phase I, Open Label Dose Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence, and Clinical Activity of UCART123 (Allogeneic Engineered T-cells Expressing Anti-CD123 Chimeric Antigen Receptor), Administered in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Gail J RobozPI
Intervention
Biological: UCART123v1.2

Phase 2/3

Early phase 13

Harini Sarva21
Ashish Saxena20
Cora Sternberg20
Ellen K. Ritchie18
Ruben Niesvizky16
Dana Jeremy Lukin14
Evelyn M. Horn14
Pinkal Desai14
Ellen J Scherl13
Daniel W Skupski12
Eleni Andreopoulou12
Jim W. Cheung12
Jia Ruan12
Massimo Cristofanilli12
Sujit Sheth12
Catherine Butkus Small11
James E. Ip11
John Allan11
Anna C Pavlick10
Alexander Ja-Ho Chou10
Aliza B Solomon10
Alpana P. Shukla10
Marshall J. Glesby10
Anna Podolanczuk9
Barbara Ma9
Catherine McGuinn9
Silvia Chiara Formenti9
Hani Lamie Ashamalla9
Kristen Marks9
Robert J. Kaner9
Shari Lipner9
Maria Teresa DeSancho8
Samuel Kim8
Andrew F. Alexis7
Erin Mulvey7
Evelyn Cantillo7
Jean W. Pape7
Sebastian A. Mayer7
Brian DeRubertis6
Conor Liston6
Darshana M Dadhania6
David M Nanus6
Joseph M Scandura6
Lok W. Yung6
Mehraneh Dorna Jafari6

Neurological Surgery19

Cardiothoracic Surgery17

Urology15

Rehabilitation Medicine13

Population Health Sciences9

Otolaryngology Head and Neck Surgery7

Pathology and Laboratory Medicine1

Pharmacology1

Show fewer

Carcinoma, Non-Small-Cell Lung27
Multiple Myeloma27
Colitis, Ulcerative26
Crohn Disease26
Myelodysplastic Syndromes26
Recurrence25
Atrial Fibrillation23
Neoplasm Metastasis23
Obesity23
Parkinson Disease21
COVID-1920
Colorectal Neoplasms18
Depression18
Cardiovascular Diseases17
Hematologic Neoplasms17
HIV Infections16
Non-alcoholic Fatty Liver Disease15
Overweight15
Melanoma13
Idiopathic Pulmonary Fibrosis12
Inflammatory Bowel Diseases12
Leukemia, Lymphocytic, Chronic, B-Cell12
Lung Neoplasms12
Lymphoma, Non-Hodgkin12
Primary Myelofibrosis12
Hypertension11
Myeloproliferative Disorders11
Alzheimer Disease10
Coronary Artery Disease10
Hypertension, Pulmonary10
Leukemia, Myelomonocytic, Chronic10
Stroke10
Urinary Bladder Neoplasms10
Cognitive Dysfunction9
Leukemia9
Lung Diseases, Interstitial9
Pulmonary Arterial Hypertension9
Burkitt Lymphoma8
Carcinoma, Renal Cell8
Chronic Pain8
Fibrosis8
Lymphoma, Follicular8
Lymphoma, Large B-Cell, Diffuse8
Adenocarcinoma Of Esophagus7
Anemia7

Radiation

Diagnostic test22

Dietary supplement14

Combination product11

Genetic6

Dates

Jun 2017 – Dec 2024

Sponsor

Cellectis, Inc

Relapsed/Refractory Acute Myeloid Leukemia

Active, not recruitingInterventional · Phase 3NCT03301506 ↗

ASSURE: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)

Sonal KumarPI

Intervention: Drug: Seladelpar 5 mg Capsule · Drug: Seladelpar 10 mg Capsule
Dates: Dec 2017 – Nov 2028 (est.)
Sponsor: Gilead Sciences, Inc.

Primary Biliary Cirrhosis

Active, not recruitingInterventional · Phase 1/2NCT03304080 ↗

A Multicenter, Phase I/II Trial of Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast Cancer

Eleni AndreopoulouPI

Intervention: Drug: Anastrozole · Drug: Palbociclib · Drug: Trastuzumab · Drug: Pertuzumab
Dates: Dec 2017 – Jul 2027 (est.)
Sponsor: Icahn School of Medicine at Mount Sinai

Breast NeoplasmsBreast Diseases

Active, not recruitingInterventional · Phase 4NCT03315910 ↗

Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites

Bradley B PuaPI

Intervention: Behavioral: Motivational Interviewing (MI) · Drug: Nicotine Replacement Therapy (NRT) · Drug: Nicotine Lozenge · Behavioral: Message Framing · Other: saliva sample
Dates: Oct 2017 – Oct 2027 (est.)
Sponsor: Memorial Sloan Kettering Cancer Center

Smoking Cessation

Active, not recruitingInterventional · Phase 1/2NCT03331198 ↗

An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)

Tsiporah B ShorePI

Intervention: Biological: JCAR017 (lisocabtagene maraleucel) · Biological: JCAR017 (lisocabtagene maraleucel) + ibrutinib · Biological: JCAR017 (lisocabtagene maraleucel) + venetoclax
Dates: Nov 2017 – Nov 2027 (est.)
Sponsor: Juno Therapeutics, Inc.

Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Small Lymphocytic

Active, not recruitingInterventional · Phase 2NCT03371719 ↗

A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)

Hani Lamie AshamallaPI

Intervention: Drug: Apalutamide · Radiation: External Beam Radiation Therapy · Other: Placebo Administration
Dates: Jun 2018 – Mar 2025· Results posted
Sponsor: NRG Oncology

Recurrent Prostate CarcinomaStage III Prostate Adenocarcinoma AJCC v7Stage IV Prostate Adenocarcinoma AJCC v7

Active, not recruitingInterventional · Phase 2NCT03375307 ↗

A Phase II Study of Olaparib (AZD2281) in Patients With Metastatic/Advanced Urothelial Carcinoma and Other Genitourinary Tumors With DNA-Repair Defects

Cora SternbergPI

Intervention: Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Procedure: Bone Marrow Biopsy · Procedure: Bone Scan · Procedure: Computed Tomography · Procedure: Magnetic Resonance Imaging · Drug: Olaparib · Procedure: Positron Emission Tomography
Dates: Nov 2020 – Dec 2026 (est.)
Sponsor: National Cancer Institute

Advanced Bladder CarcinomaAdvanced Genitourinary System CarcinomaMetastatic Bladder Carcinoma+3 more

Active, not recruitingInterventional · Not applicableNCT03400215 ↗

Gradient-Echo Spectroscopic Imaging Study of Saturated Fat and Breast Cancer

Gene KimPI

Intervention: Diagnostic test: Diagnostic Breast Cancer Scan · Diagnostic test: Research Scan for Gradient-echo Spectroscopic Imaging (GSI)
Dates: Jul 2018 – Apr 2026 (est.)
Sponsor: Weill Medical College of Cornell University

Breast Cancer

Active, not recruitingInterventional · Phase 2NCT03407144 ↗

An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults With Newly Diagnosed Classical Hodgkin Lymphoma With Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)

Lisa Giulino RothPI

Intervention: Biological: pembrolizumab · Drug: doxorubicin · Drug: vinblastine · Drug: dacarbazine · Drug: cyclophosphamide · Drug: vincristine · Drug: prednisone/prednisolone · Drug: bleomycin · Drug: etoposide · Radiation: Radiotherapy (RT)
Dates: Apr 2018 – Feb 2027 (est.)
Sponsor: Children's Oncology Group

Hodgkin Lymphoma

Active, not recruitingInterventional · Phase 4NCT03417388 ↗

Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD

Nupoor NarulaPI

Intervention: Drug: High dose potent statin · Drug: ACE-I (lisinopril) or ARB (losartan) · Drug: Aspirin 81 enteric coated tablet daily · Behavioral: Lifestyle Counseling · Behavioral: Quality of Life Questionnaires
Dates: Feb 2018 – May 2024
Sponsor: University of Florida

Coronary Artery Disease

RecruitingInterventional · Phase 2/3NCT03435796 ↗

Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells

Roger N PearsePI

Intervention: Genetic: Gene-modified (GM) T cell therapy
Dates: Jul 2018 – May 2043 (est.)
Sponsor: Celgene Corporation

Neoplasms

RecruitingInterventional · Phase 1/2NCT03449238 ↗

Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients

Silvia Chiara FormentiPI

Intervention: Drug: Pembrolizumab
Dates: Nov 2018 – Dec 2028 (est.)
Sponsor: Weill Medical College of Cornell University

Metastatic Breast CancerBrain Metastases

Active, not recruitingInterventional · Phase 2/3NCT03466411 ↗

A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

Ellen J ScherlPI

Intervention: Drug: Guselkumab Dose 1 · Drug: Guselkumab Dose 2 · Drug: Guselkumab Dose 3 · Drug: Guselkumab Dose 4 · Drug: Guselkumab Dose 5 · Drug: Guselkumab · Drug: Ustekinumab · Drug: Placebo
Dates: Apr 2018 – Oct 2023· Results posted
Sponsor: Janssen Research & Development, LLC

Crohn's Disease

Active, not recruitingInterventional · Phase 2NCT03485209 ↗

Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors

Elizabeta Cristina PopaPI

Intervention: Drug: tisotumab vedotin · Drug: pembrolizumab · Drug: carboplatin · Drug: cisplatin
Dates: Jun 2018 – Mar 2026
Sponsor: Seattle Genetics, Inc.

Colorectal NeoplasmsCarcinoma, Non-Small-Cell LungExocrine Pancreatic Cancer+1 more

Active, not recruitingInterventional · Not applicableNCT03487185 ↗

A Randomized Trial of Continuous Positive Airway Pressure (CPAP) for Sleep Apnea in Pregnancy

Daniel W SkupskiPI

Intervention: Device: Continuous Positive Airway Pressure · Other: Sleep Advice Control
Dates: Aug 2018 – Oct 2026 (est.)
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Develop

Obstructive Sleep Apnea of AdultPreeclampsiaObstetrical Complications

Active, not recruitingInterventional · Phase 3NCT03488693 ↗

TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

Hani Lamie AshamallaPI

Intervention: Radiation: Radiation · Other: No Radiation
Dates: Oct 2018 – Sep 2027 (est.)
Sponsor: Canadian Cancer Trials Group

Breast Cancer

Active, not recruitingInterventional · Not applicableNCT03499236 ↗

RELIEVE-HF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure

Maria KarasPI

Intervention: Device: V-Wave Interatrial Shunt · Other: Control
Dates: Sep 2018 – Oct 2023
Sponsor: V-Wave Ltd.

Heart Failure

Active, not recruitingInterventional · Phase 2NCT03505320 ↗

A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy and in Combination With Chemotherapy and/or Immunotherapy in Subjects With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and Locoregional Gastric or GEJ Adenocarcinoma Whose Are Claudin (CLDN) 18.2 Positive

Manish A ShahPI

Intervention: Drug: zolbetuximab · Drug: oxaliplatin · Drug: leucovorin · Drug: fluorouracil · Drug: Pembrolizumab · Drug: folinic acid · Drug: nivolumab · Drug: Docetaxel
Dates: Jun 2018 – Jun 2027 (est.)
Sponsor: Astellas Pharma Inc.

Pharmacokinetics of ZolbetuximabGastric CancerGastro-esophageal Junction (GEJ) Cancer+2 more

Active, not recruitingInterventional · Phase 3NCT03533582 ↗

Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)

Alexander Ja-Ho ChouPI

Intervention: Procedure: Biospecimen Collection · Drug: Carboplatin · Drug: Cisplatin · Drug: Doxorubicin · Drug: Etoposide · Drug: Fluorouracil · Drug: Gemcitabine · Drug: Irinotecan · Drug: Oxaliplatin · Other: Patient Observation · Procedure: Resection · Drug: Sorafenib · Drug: Vincristine Sulfate
Dates: May 2018 – Mar 2027 (est.)
Sponsor: Children's Oncology Group

Childhood Hepatocellular CarcinomaChildhood Malignant Liver NeoplasmFibrolamellar Carcinoma+2 more

Active, not recruitingInterventional · Phase 2NCT03547973 ↗

A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer

Scott T. TagawaPI

Intervention: Drug: Sacituzumab Govitecan-hziy · Drug: Pembrolizumab · Drug: Cisplatin · Drug: Avelumab · Drug: Zimberelimab · Drug: Carboplatin · Drug: Gemcitabine · Drug: Domvanalimab · Drug: Enfortumab Vedotin
Dates: Aug 2018 – Apr 2030 (est.)
Sponsor: Immunomedics, Inc.

Metastatic Urothelial Cancer

‹ Prev 1 2 3 4 5…56 57 58 59 60 Next ›